Global RNAi for Therapeutic Market By Type (siRNA, miRNA, and shRNA), By Application (Cancer, Cardiovascular, and HBV), By Region and Key Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2020-2029
- 134704
- 12-Dec
- PDF/PPT/Word
-
Report Details
The report on RNAi for Therapeutic Market offers in-depth analysis on market trends, drivers, restraints, opportunities etc. Along with qualitative information, this report include the quantitative analysis of various segments in terms of market share, growth, opportunity analysis, market value, etc. for the forecast years. The global rnai for therapeutic market is segmented on the basis of Type, Application and geography.
The worldwide market for RNAi for Therapeutic Market is expected to grow at a CAGR of roughly x.x% over the next ten years and will reach US$ XX.X Mn in 2028, from US$ XX.X Mn in 2018, according to a new Market.us (Prudour Research) study.
RNAi for Therapeutic Market Scope:
By type, the market is segmented into siRNA, miRNA and shRNA. By Application, the market is divided into Cancer, Cardiovascular and HBV. Based on geography, market is analyzed across North America, Europe, Asia-Pacific, Latin America and Middle East and Africa. Major players profiled in the report include Alnylam Pharmaceuticals, Arbutus Biopharma (Tekmira), Arrowhead, Dicerna Pharmaceuticals, Mirna Therapeutics, Quark Pharmaceuticals, RXi Pharmaceuticals, Silence Therapeutics, Benitec Biopharma, miRagen Therapeutics, Sylentis, Gradalis, Sirnaomics and Silenseed.
Key Market Segments
Type
siRNA
miRNA
shRNAApplication
Cancer
Cardiovascular
HBVKey Market Players included in the report:
Alnylam Pharmaceuticals
Arbutus Biopharma (Tekmira)
Arrowhead
Dicerna Pharmaceuticals
Mirna Therapeutics
Quark Pharmaceuticals
RXi Pharmaceuticals
Silence Therapeutics
Benitec Biopharma
miRagen Therapeutics
Sylentis
Gradalis
Sirnaomics
SilenseedReasons to Get this Report:
In an insight outlook, this research report has dedicated to several quantities of analysis – industry research (global industry trends) and RNAi for Therapeutic Market share analysis of high players, along with company profiles and which collectively include about the fundamental opinions regarding the market landscape. Emerging and high-growth sections of RNAi for Therapeutic Market, high-growth regions, and market drivers, restraints and also market chances.
The analysis covers RNAi for Therapeutic Market and its advancements across different industry verticals as well as regions. It targets estimating the current market size and growth potential of the global RNAi for Therapeutic Market across sections such as also Application and representatives.
Additionally, the analysis also has a comprehensive review of the crucial players on the RNAi for Therapeutic Market together side their company profiles, SWOT analysis, latest advancements and business plans.The analysis objectives of the report are:
To equitably share in-depth info regarding the crucial elements impacting the increase of industry (growth capacity, chances, drivers and industry-specific challenges and risks).
To know the RNAi for Therapeutic Market by pinpointing its many subsegments.
To profile the important players and analyze their growth plans.
To endeavor the amount and value of RNAi for Therapeutic sub-markets, depending on key regions (various vital states).
To analyze RNAi for Therapeutic Market concerning growth trends, prospects and also their participation in the entire sector.
To examine and study the RNAi for Therapeutic Market size (volume & value) from the company, essential regions/countries, products and Application, background information from 2012 to 2018 and also prediction to 2028.
Primary worldwide RNAi for Therapeutic Market manufacturing companies, to specify, clarify and analyze the product sales amount, value and market share, market rivalry landscape, SWOT analysis and development plans next coming years.
To examine competitive progress such as expansions, arrangements, new product launches and acquisitions on the market. -
Table Of Content
1. RNAi for Therapeutic Market Introduction
1.1. Definition
1.2. Taxonomy
1.3. Research Scope2. Executive Summary2.1. Key Findings by Major Segments
2.2. Top strategies by Major Players3. Global RNAi for Therapeutic Market Overview3.1. RNAi for Therapeutic Market Dynamics
3.1.1. Drivers
3.1.2. Opportunities
3.1.3. Restraints
3.1.4. Challenges3.2. PESTLE Analysis
3.3. Opportunity Map Analysis
3.4. PORTER’S Five Forces Analysis
3.5. Market Competition Scenario Analysis
3.6. Product Life Cycle Analysis
3.7. Opportunity Orbits
3.8. Manufacturer Intensity Map4. Global RNAi for Therapeutic Market Value (US$ Mn), Share (%), and Growth Rate (%) Comparison by Type, 2012-20284.1. Global RNAi for Therapeutic Market Analysis by Type: Introduction
4.2. Market Size and Forecast by Region
4.3. siRNA
4.4. miRNA
4.5. shRNA5. Global RNAi for Therapeutic Market Value (US$ Mn), Share (%), and Growth Rate (%) Comparison by Application, 2012-20285.1. Global RNAi for Therapeutic Market Analysis by Application: Introduction
5.2. Market Size and Forecast by Region
5.3. Cancer
5.4. Cardiovascular
5.5. HBV6. Global RNAi for Therapeutic Market Value (US$ Mn), Share (%), and Growth Rate (%) Comparison by Region, 2012-20286.1. North America
6.1.1. North America RNAi for Therapeutic Market: Regional Trend Analysis
6.1.1.1. US
6.1.1.2. Canada
6.1.1.3. Mexico6.2. Europe
6.2.1. Europe RNAi for Therapeutic Market: Regional Trend Analysis
6.2.1.1. Germany
6.2.1.2. France
6.2.1.3. UK
6.2.1.4. Russia
6.2.1.5. Italy
6.2.1.6. Rest of Europe6.3. Asia-Pacific
6.3.1. Asia-Pacific RNAi for Therapeutic Market: Regional Trend Analysis
6.3.1.1. China
6.3.1.2. Japan
6.3.1.3. Korea
6.3.1.4. India
6.3.1.5. Rest of Asia6.4. Latin America
6.4.1. Latin America RNAi for Therapeutic Market: Regional Trend Analysis
6.4.1.1. Brazil
6.4.1.2. Argentina
6.4.1.3. Rest of Latin America6.5. Middle East and Africa
6.5.1. Middle East and Africa RNAi for Therapeutic Market: Regional Trend Analysis
6.5.1.1. GCC
6.5.1.2. South Africa
6.5.1.3. Israel
6.5.1.4. Rest of MEA
7. Global RNAi for Therapeutic Market Competitive Landscape, Market Share Analysis, and Company Profiles7.1. Market Share Analysis
7.2. Company Profiles
7.3. Alnylam Pharmaceuticals7.3.1. Company Overview
7.3.2. Financial Highlights
7.3.3. Product Portfolio
7.3.4. SWOT Analysis
7.3.5. Key Strategies and Developments7.4. Arbutus Biopharma (Tekmira)7.4.1. Company Overview
7.4.2. Financial Highlights
7.4.3. Product Portfolio
7.4.4. SWOT Analysis
7.4.5. Key Strategies and Developments7.5. Arrowhead7.5.1. Company Overview
7.5.2. Financial Highlights
7.5.3. Product Portfolio
7.5.4. SWOT Analysis
7.5.5. Key Strategies and Developments7.6. Dicerna Pharmaceuticals7.6.1. Company Overview
7.6.2. Financial Highlights
7.6.3. Product Portfolio
7.6.4. SWOT Analysis
7.6.5. Key Strategies and Developments7.7. Mirna Therapeutics7.7.1. Company Overview
7.7.2. Financial Highlights
7.7.3. Product Portfolio
7.7.4. SWOT Analysis
7.7.5. Key Strategies and Developments7.8. Quark Pharmaceuticals7.8.1. Company Overview
7.8.2. Financial Highlights
7.8.3. Product Portfolio
7.8.4. SWOT Analysis
7.8.5. Key Strategies and Developments7.9. RXi Pharmaceuticals7.9.1. Company Overview
7.9.2. Financial Highlights
7.9.3. Product Portfolio
7.9.4. SWOT Analysis
7.9.5. Key Strategies and Developments7.10. Silence Therapeutics7.10.1. Company Overview
7.10.2. Financial Highlights
7.10.3. Product Portfolio
7.10.4. SWOT Analysis
7.10.5. Key Strategies and Developments7.11. Benitec Biopharma7.11.1. Company Overview
7.11.2. Financial Highlights
7.11.3. Product Portfolio
7.11.4. SWOT Analysis
7.11.5. Key Strategies and Developments7.12. miRagen Therapeutics7.12.1. Company Overview
7.12.2. Financial Highlights
7.12.3. Product Portfolio
7.12.4. SWOT Analysis
7.12.5. Key Strategies and Developments7.13. Sylentis7.13.1. Company Overview
7.13.2. Financial Highlights
7.13.3. Product Portfolio
7.13.4. SWOT Analysis
7.13.5. Key Strategies and Developments7.14. Gradalis7.14.1. Company Overview
7.14.2. Financial Highlights
7.14.3. Product Portfolio
7.14.4. SWOT Analysis
7.14.5. Key Strategies and Developments7.15. Sirnaomics7.15.1. Company Overview
7.15.2. Financial Highlights
7.15.3. Product Portfolio
7.15.4. SWOT Analysis
7.15.5. Key Strategies and Developments7.16. Silenseed7.16.1. Company Overview
7.16.2. Financial Highlights
7.16.3. Product Portfolio
7.16.4. SWOT Analysis
7.16.5. Key Strategies and Developments8. Assumptions and Acronyms
9. Research Methodology
10. Contact -
Inquiry Before Buying
-
Request Sample
